Damaged Collagen Down 41%, BASF Unveils Precision Peptide NeoHelix Regenerate
Skin aging is not really about collagen disappearing. It is about damaged collagen piling up. Oxidation, glycation, and UV stress break collagen molecules over time, and these corrupted fibers erode the density and bounce of the dermis. At in-cosmetics Global 2026 in Paris, BASF unveiled NeoHelix Regenerate, a precision peptide designed to target exactly this damaged fraction.
56 Days, Skin in the 60 to 70 Range
The clinical data is what makes this launch interesting. In an in vivo study with five women aged 60 to 70, 56 days of NeoHelix Regenerate application delivered a 41% reduction in damaged collagen. Over the same window, biopsy analysis showed endogenous hyaluronic acid rising by 65%. The skin was not being flooded with external hyaluronic acid. It was producing more on its own.
The sample is small. Five subjects is not a large randomized controlled trial. But the study design is invasive, using biopsy to directly quantify damaged collagen in mature skin, which is a harder test than surface measurements. The direction and magnitude of the numbers merit attention.
What Precision Actually Means
Peptides are an old category in skin science. Matrixyl, argireline, copper peptides are familiar names. Most of these work by pushing collagen synthesis with a broad signal or by inhibiting enzymes that break collagen down.
Precision peptides go one step further. Instead of flooding the system, they target specific receptors in the skin’s existing repair machinery, reactivating pathways that clear damaged collagen and rebalance new collagen production. The logic shifts from supplying materials to waking up the repair system already built into the cell.
SkinNexus Collag3n, Collagen III from Yeast Fermentation
BASF also introduced SkinNexus Collag3n at the same event. This is a recombinant collagen III fragment produced through biotechnology in vegan yeast, carrying a 100% human-identical sequence and behaving biomimetically within the extracellular matrix (ECM, the structural protein network between skin cells).
Collagen III is proportionally high in young skin and plays a central role in flexibility and wound healing. As skin ages, the ratio of type III to type I drops sharply, which translates into the thinning feel of mature skin. Delivering a recombinant collagen III fragment directly is an attempt to correct that ratio rather than just add more type I scaffolding.
How This Connects to Ingestible Collagen
Both ingredients are cosmetic actives, meaning they live in topical formulations. That raises a fair question about how ingestible collagen fits in.
Oral collagen peptides break down into amino acids and short peptide fragments during digestion. Some low molecular weight peptides such as Gly-Pro-Hyp are absorbed into the bloodstream and stimulate dermal fibroblasts, according to a growing base of research. The BASF announcement signals that topical delivery is getting more precise at the molecular level, which does not replace ingestible strategies but complements them from a different angle.
What the Market Is Reading
This launch also fits a broader shift toward evidence-based beauty. Storytelling alone is no longer enough. Consumers are increasingly asking for clinical data, molecular mechanisms, and biomimetic credibility.
Redefining skin aging as a matter of collagen quality rather than collagen quantity, and shifting from external supply to reactivation of the skin’s own repair pathways, gives a useful signal about where ingredient science is heading. The numbers, 56 days, 41%, 65%, suggest that the shift is backed by lab work rather than pure marketing language.